Levulan (Aminolevulinic Acid HCl) Patent Expiration, LOE Window & CMS Spending

Levulan (Aminolevulinic Acid HCl) by Sun Pharmaceutical: FDA Orange Book LOE 2038-01-12, 0 AB generics, $1.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN020965 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-01-12
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.0M
2024 Medicare Part D Spend$211K
2024 Medicaid Spend$795K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel